Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …

Emerging evidence indicates that the detection and clearance of cancer cells via
phagocytosis induced by innate immune checkpoints play significant roles in tumor …

The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted
through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein …

Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy
continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host …

Here, we describe a combination strategy of black phosphorus (BP)-based photothermal
therapy together with anti-CD47 antibody (aCD47)-based immunotherapy to synergistically …

Inhibitory immune checkpoint blockade has been one of the most significant advances in
anticancer therapy of the past decade. Research so far has largely focused on improving …

CD47 acts as a" don't eat me" signal that protects cells from phagocytosis by binding and
activating its receptor SIPRA on macrophages. CD47 suppresses multiple different pro …

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill
cancer. The success of CAR-T cell therapies highlights the promise of programmed …

Tumor-associated macrophage (TAM) phagocytic activity is emerging as a new mechanism
to harness for cancer treatment. Currently, many approaches are investigated at the …